Brief: Oryzon Presents Promising Preliminary Results from Phase IB FRIDA Trial at EHA-2024

ORYZON Genomics SA

14/06/2024 08:08

June 14 (Reuters) - Oryzon Genomics SA  ORY.MC :
    * PRESENTS PRELIM DATA FROM ONGOING PHASE IB TRIAL WITH
IADADEMSTAT PLUS GILTERITINIB IN RELAPSED/REFRACTORY FLT3-MUT
AML PATIENTS AT EHA-2024
    * DATA FROM FIRST TWO COHORTS SHOW COMBINATION OF
IADADEMSTAT PLUS
GILTERITINIB WAS SAFE AND SHOW STRONG ANTILEUKEMIC ACTIVITY
    * THIRD COHORT IS ONGOING FOLLOWING FDA’S OPTIMUS GUIDANCE

Source text:  ID:nCNMgHRKl 
Further company coverage:  ORY.MC 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))